Enter Symbol:
OSI PHARMACEUTICALS INC
Biotechnology
OSIP @ Yahoo Finance OSIP Option @ Yahoo Finance
Stock Details
Current Price	High	Value Change	Percent Change	Dividend	Previous Close
$ 57.49	$ 57.51	$ -0.01	-0.02%	0.00	$ 57.50
Opening Price	Low	Volume	Market Cap	Average Volume	P/E
$ 57.49	$ 57.48	4.55M	3.52B	2.49M	52.92
Pivot Table
R2 R1 Pivot S1 S2 57.52 57.50 57.49 57.47 57.46

OSI Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of oncology products for cancer patients in the United States. Its flagship product, Tarceva, is an oral, once-a-day, small molecule inhibitor of the epidermal growth factor receptor. The company also markets Novantrone for the approved oncology indications; and Gelclair for the relief of pain associated with oral mucositis. Its other drug candidates include OSI-7904L, a liposomal formulation of a potent thymidylate synthase inhibitor, which is in phase II study; OSI-461, an inhibitor of cGMP phosphodiesterases, which is in phase I dose optimization study; and OSI-930, a tyrosine kinase inhibitor, which is in preclinical research stage. In addition, OSI Pharmaceuticals, through its collaborative drug discovery program, develops CP-547,632, which targets vascular endothelial growth factor receptor and is in Phase II and Phase I trials; CP-868,596 that targets tumor derived angiogenesis and is in Phase I trials; and CP-724,714, which is an oral inhibitor of epidermal growth factor receptor 2 and is in Phase I clinical trial. Further, its subsidiary, Prosidion Limited, specializes in diabetes and obesity treatment in the United Kingdom. The company has collaboration agreements with Pfizer, Inc.; Cold Spring Harbor Laboratory; EiRX Therapeutics plc; Genentech, Inc.; PR Pharmaceuticals, Inc.; and Roche. OSI Pharmaceuticals is headquartered in Melville, New York.